Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...
dermatologyadvisor8d
Long-Term Lebrikizumab in AD Is Effective Despite Inadequate Short-Term Response
Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.
Healio9d
‘Don’t give up’: Long-term lebrikizumab for AD may benefit initial nonresponders
Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...
pulmonologyadvisor15d
Automated Analysis of 2D Camera Recordings Improves Detection of Isolated REM Sleep Behavior Disorder
Researchers found that patients with iRBD showed a higher number of shorter movements and immobility periods. HealthDay News — Automated analysis of two-dimensional (2D) camera recordings can improve ...
thecardiologyadvisor.com25d
2024 Novel Drug and Biological Product Approvals
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products approved by the Food and Drug ...
Pharmaceutical Technology25d
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
Eisai and Biogen’s antibody is currently infused every two weeks at hospitals and dedicated infusion sites. Image credit: Shutterstock/ AtlasStudio. Eisai and Biogen are one step away from deploying a ...